A previous report demonstrated that global deletion of NOV/CCN3 in mice with HFD exhibited improved glucose tolerance, insulin sensitivity, and metabolic parameters [4], suggesting that NOV/CCN3 is involved in obesity-associated insulin resistance and can be a novel target for obesity management. This evidence concerns the gene CCN3 and obesity due to melanocortin 4 receptor deficiency.